Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, Joern Rau, Sven Mahner, Patricia Pautier, Ahmed El-Balat, Jean-Emmanuel Kurtz, Ulrich Canzler, Jalid Sehouli, Martin L Heubner, Andreas D Hartkopf, Klaus Baumann, Annette Hasenburg, Lars C Hanker, Antje Belau, Barbara Schmalfeldt, Dominik Denschlag, Tjoung-Won Park-Simon, Frédéric Selle, Christian Jackisch, Alexander Burges, Hans-Joachim Lück, Günter Emons, Werner Meier, Martina Gropp-Meier, Willibald Schröder, Nikolaus de Gregorio, Felix Hilpert, Philipp Harter
PURPOSE: To compare standard versus extended duration of bevacizumab treatment in combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV ovarian cancer. METHODS: In this multicenter, open-label, randomized phase III trial (ClinicalTrials.gov identifier: NCT01462890), patients with newly diagnosed International Federation of Gynecology and Obstetrics stage IIB-IV epithelial ovarian, fallopian tube, or peritoneal cancer underwent primary cytoreductive surgery followed by six cycles of chemotherapy (paclitaxel 175 mg/m2 plus carboplatin area under the curve 5 once every 3 weeks) and bevacizumab (15 mg/kg once every 3 weeks)...
February 1, 2023: Journal of Clinical Oncology